SXC first quarter revenue increases 56% to $1.7 billion

SXC Health Solutions Corp. ("SXC" or the "Company") (NASDAQ: SXCI, TSX: SXC), a leading provider of technology and pharmacy benefit management ("PBM") services, announces its financial results for the three-month period ended March 31, 2012.

Q1 2012 Highlights

• Revenue grew 56% on a year over year basis to $1.7 billion, compared to $1.1 billion in Q1 2011
  
• Gross profit increased 74% to $110.4 million, compared to $63.6 million in Q1 2011
  
• Net income increased 44% to $26.3 million, or $0.42 per share (fully-diluted), compared to $18.3 million, or $0.29 per share (fully-diluted), in Q1 2011
  
• EBITDA increased 62% to $54.4 million, compared to $33.5 million in Q1 2011
  
• Non-GAAP adjusted earnings per share¹ (fully-diluted), increased 58% to $0.52, compared to $0.33 in Q1 2011
  
• Cash from operations increased to $56.2 million compared to $0.8 million in Q1 2011
  
• Adjusted prescription claim volume for the PBM segment increased 61.5% to 34.4 million, compared to 21.3 million in Q1 2011
  
• Transaction processing volume for the HCIT segment increased to 119.4 million compared to 99.2 million in Q1 2011
  
• Generic dispense rate increased to 80% compared to 78% in Q1 2011
  
• Successfully converted one HCIT client to PBM services in the quarter
  
• Completed the acquisition of HealthTran LLC ("HealthTran"), a full-service pharmacy benefit manager
  
• Awarded $1.2 billion contract over a 3 year term with Blue Cross & Blue Shield of Rhode Island
  
• Announced merger with Catalyst Health Solutions, Inc. (NASDAQ: CHSI), subsequent to the end of the period

"Q1 was another quarter where we were hitting on all cylinders and utilizing the momentum we have built. Our results from operations continue to set new records due to successfully executing our plan, and these strong results have set the table for a successful 2012.  Our contract win with Blue Cross & Blue Shield of Rhode Island continues to showcase our ability to successfully compete for some of the largest health plan opportunities in the market.  The integration of HealthTran continued to move along successfully and provided a positive impact to our Q1 results.  Along with these great results, the Company has been energized with our recently announced merger with Catalyst, and we're all looking forward to entering the next chapter of SXC.  All of these factors have put us in a great position to deliver a record setting 2012 and continued growth moving forward," said Mark Thierer, Chairman and CEO of SXC.

Financial Review

Revenue and Gross Profit segmented by PBM and HCIT:

SXC evaluates segment performance based on revenue and gross profit. Reconciliations of the Company's business segments to the consolidated financial statements for the three months ended March 31, 2012 and 2011 are as follows:

Three months ended March 31, (unaudited, in thousands)

PBM Revenue
PBM revenue increased $0.6 billion, or 56.8%, to $1.7 billion in Q1 2012 compared to $1.1 billion in Q1 2011. The increase in revenue is primarily due to increased prescription claim volume as a result of new customer wins, conversion of clients from HCIT to full service PBM contracts, as well as revenues generated from the acquisition of HealthTran, which closed in January 2012.

HCIT Revenue
HCIT revenue increased $10.2 million, or 39.7%, to $36.0 million in Q1 2012 compared to $25.7 million in Q1 2011. The increase was primarily due to an increase in revenues earned from transaction processing as well as revenues from HealthTran's HCIT customer base.

Consolidated Gross Profit
Gross profit for Q1 2012 increased $46.8 million, or 73.6%, to $110.4 million compared to $63.6 million in Q1 2011, mostly due to incremental PBM revenues generated from new customer starts in 2012 and the HealthTran acquisition. Gross profit percentage increased to 6.4% of revenue in Q1 2012 from 5.8% of revenue in Q1 2011 due to the higher gross profit percentage from both PBM and HCIT segments, due in part to the HealthTran acquisition, as well as higher utilization of generics and specialty medications.

Selling, General and Administration ("SG&A") Costs
SG&A costs for Q1 2012 were $53.6 million compared to $27.4 million in Q1 2011. SG&A costs consist primarily of employee costs in addition to professional services costs, facilities and costs not related to cost of revenue. SG&A costs have increased due to the addition of operating costs related to the Company's recent acquisitions, including HealthTran and PTRX Inc. as well as additional resources added to support the growth of the PBM segment.

Net Income
The Company reported Q1 2012 net income of $26.3 million, or $0.42 per share (fully-diluted), compared to $18.3 million, or $0.29 per share (fully-diluted), in Q1 2011.

Adjusted EPS (fully-diluted), which excludes all transaction-related amortization of intangible assets, net of tax, increased 58% to $0.52 per share (fully-diluted), compared to $0.33 per share (fully-diluted) in Q1 2011.

EBITDA
Q1 2012 EBITDA increased 62% to $54.4 million compared to $33.5 million in Q1 2011. The growth in EBITDA was due primarily to new contract wins, increased utilization of cost effective generics as well as additional business generated from the recent acquisitions and their associated synergies.

Cash from Operations
For Q1 2012, the Company generated $56.2 million of cash from operations, compared to $0.8 million generated in cash from operations during Q1 2011. The increased transaction volume in the PBM segment, propelled by new customer starts during Q1 2012, as well as the additional business generated as a result of the Company's recent acquisitions, were the primary drivers of increased operating cash flow during Q1 2012.

2012 Full Year Financial Guidance
With today's announcement, SXC is re-affirming its 2012 full year financial targets, which does not take into account the impact of the transaction, or related costs of the Company's announced merger with Catalyst which is expected to close in the second half of 2012:

• Revenue of $6.8 to $6.9 billion.
• EBITDA of $248 to $255 million.
• GAAP EPS (fully-diluted) of $1.96 to $2.04.
• Adjusted EPS (fully-diluted) of $2.37 to $2.45 (excluding all transaction-related amortization).